Fig. 2: effects of γCdcPLI inhibitor on the viability and cell cycle progression. Viability assay of both (A) Leishmania (Leishmania) amazonensis promastigotes and (B) Macrophages C57 treated with γCdcPLI ranging from 0.781 to 50 µg/mL for 24 h. For the positive controls of viability, cells and parasites were treated with RPMI and LIT media only, respectively. (C) A comparative analysis of viability between the effects of γCdcPLI on cells and parasites. (D, E) Representative histograms and graph showed that γCdcPLI (50 µg/mL) promoted a significant cell cycle arrest at G1 phase at 24 h post-treatment. Data are expressed as mean ± standard deviation (SD). Significant differences were determined using one-way analysis of variance (ANOVA) and Dunnett’s multiple comparisons test. Differences were considered significant when p < 0.05.